Clinical Trial Results:
Effect of Calcipotriol plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 months) with Scalp and Body Psoriasis
Summary
|
|
EudraCT number |
2013-001538-16 |
Trial protocol |
GB DE FR RO |
Global end of trial date |
13 Feb 2018
|
Results information
|
|
Results version number |
v1 |
This version publication date |
26 Aug 2018
|
First version publication date |
26 Aug 2018
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
LP0076-1017
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02038569 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
LEO Pharma A/S
|
||
Sponsor organisation address |
Industriparken 55, Ballerup, Denmark, 2750
|
||
Public contact |
Clinical Disclosure Specialist, LEO Pharma A/S, +45 44945888, disclosure@leo-pharma.com
|
||
Scientific contact |
Clinical Disclosure Specialist, LEO Pharma A/S, +45 44945888, disclosure@leo-pharma.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
05 Aug 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
13 Feb 2018
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
13 Feb 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective was to evaluate the safety of once daily use of calcipotriol (50 mcg/g) plus betamethasone (0.5 mg/g) (as dipropionate) gel in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis.
|
||
Protection of trial subjects |
This clinical trial was conducted in accordance with the revision current at the start of the trial of the World Medical Association’s Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. All subjects received written and verbal information concerning the clinical trial. This information emphasised that participation in the clinical trial was voluntary and that the subject could withdraw from the clinical trial at any time and for any reason. All subjects and their legally acceptable representatives were given an opportunity to ask questions and were given sufficient time to consider before consenting. Subjects who were not of legal age gave assent to their participation in the trial. The subject’s and legally acceptable representatives' signed and dated informed consent and assent to participate in the clinical trial were obtained prior to any trial related activities being carried out in accordance with ICH Good Clinical Practice (GCP) Section 4.8 and all applicable laws and regulations.
Overdosage with calcipotriol may be associated with hypercalcaemia, and clinically important hypercalcaemia could be managed at the investigator’s discretion with rehydration, biphosphonate administration or according to local instructions.
Overdosage with betamethasone dipropionate may result in suppression of the pituitary adrenal function, and could be treated symptomatically at the investigator's discretion.
There is a risk of allergic hypersensitivity reactions with administration of Cortrosyn®/Synacthen®. Prior to the injection, the physician administering the injection was prepared to treat any possible hypersensitivity reactions.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
07 Mar 2014
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Romania: 45
|
||
Country: Number of subjects enrolled |
United Kingdom: 11
|
||
Country: Number of subjects enrolled |
Poland: 14
|
||
Country: Number of subjects enrolled |
France: 7
|
||
Country: Number of subjects enrolled |
Germany: 21
|
||
Country: Number of subjects enrolled |
Canada: 13
|
||
Country: Number of subjects enrolled |
United States: 14
|
||
Worldwide total number of subjects |
125
|
||
EEA total number of subjects |
98
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
125
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||
Recruitment
|
|||||||||||||||
Recruitment details |
- | ||||||||||||||
Pre-assignment
|
|||||||||||||||
Screening details |
Male or female, 12 to 16 years 11 months, psoriasis on body and scalp. •10-35% BSA; ≥20% scalp; at least moderate severity for subjects performing HPA assessment. •≥3% BSA; ≥10% scalp; at least mild severity for subjects not performing HPA assessment. 125 screened. 107 assigned to treatment, 1 lost to follow up and, 17 didn't meet entry criteria | ||||||||||||||
Period 1
|
|||||||||||||||
Period 1 title |
Overall period
|
||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||
Blinding used |
Not blinded | ||||||||||||||
Arms
|
|||||||||||||||
Arm title
|
LEO 80185 | ||||||||||||||
Arm description |
This arm contains all 107 subjects that were assigned to treatment and constitutes the full analysis set and the safety analysis set. 31 subjects in this arm performed additional hypothalamic-pituitary axis assessments and constitute the per protocol analysis set. | ||||||||||||||
Arm type |
Experimental | ||||||||||||||
Investigational medicinal product name |
LEO 80185
|
||||||||||||||
Investigational medicinal product code |
|||||||||||||||
Other name |
Daivobet® gel , Xamiol® gel, Dovobet gel ®, and Taclonex® Topical Suspension
|
||||||||||||||
Pharmaceutical forms |
Gel
|
||||||||||||||
Routes of administration |
Topical use
|
||||||||||||||
Dosage and administration details |
LEO 80185 gel is formulated as a gel containing Calcipotriol 50 mcg/g (as hydrate) and Betamethasone 0.5 mg/g (as dipropionate).LEO 80185 gel was applied once daily to all affected areas of the scalp and body. For subjects aged 12 to less than 15 years with a body surface area below 1.3 m2, the maximum weekly dosage of LEO 80185 gel was 55 g gel per week. For subjects aged 12 to less than 15 years with a body surface area above 1.3 m2 and subjects older than 15 years with a body surface area below 1.3 m2, the maximum weekly dosage of LEO 80185 gel was 75 g gel per week. For subjects aged older than 15 years with a body surface area above 1.3 m2, the maximum weekly dosage of LEO 80185 gel was 100 g gel per week. No maximum weekly dosage of LEO 80185 gel was defined for subjects performing HPA assessments.
|
||||||||||||||
|
|||||||||||||||
Notes [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: A total of 125 subjects were screened in the trial. Out of the 125 screened subjects, 17 were screening failures, and 1 subject screening but was immediately lost to follow-up. The remaining 107 subjects were assigned tothe treatment. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall period
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Per protocol analysis set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
For the analysis of the results from the ACTH-challenge test, the per protocol analysis set was defined by including the subjects performing HPA axis assessments from the full analysis set, but was to exclude the subjects who did not apply any LEO 80185 gel, met the inclusion criterion concerning evidence of adrenal function suppression at baseline, or provide any results for the ACTH-challenge test after receiving IMP.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Full analysis set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
107 subjects who applied LEO 80185 gel at least once and were included in the analysis of efficacy.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Safety analysis set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Safety analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
107 subjects who applied LEO 80185 gel at least once and for whom either the presence or confirmed absence of adverse events was available.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
LEO 80185
|
||
Reporting group description |
This arm contains all 107 subjects that were assigned to treatment and constitutes the full analysis set and the safety analysis set. 31 subjects in this arm performed additional hypothalamic-pituitary axis assessments and constitute the per protocol analysis set. | ||
Subject analysis set title |
Per protocol analysis set
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
For the analysis of the results from the ACTH-challenge test, the per protocol analysis set was defined by including the subjects performing HPA axis assessments from the full analysis set, but was to exclude the subjects who did not apply any LEO 80185 gel, met the inclusion criterion concerning evidence of adrenal function suppression at baseline, or provide any results for the ACTH-challenge test after receiving IMP.
|
||
Subject analysis set title |
Full analysis set
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
107 subjects who applied LEO 80185 gel at least once and were included in the analysis of efficacy.
|
||
Subject analysis set title |
Safety analysis set
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
107 subjects who applied LEO 80185 gel at least once and for whom either the presence or confirmed absence of adverse events was available.
|
|
|||||||||||||||||||||
End point title |
Adverse Drug Reactions (ADRs) [1] | ||||||||||||||||||||
End point description |
Number of Adverse Drug Reactions (ADRs) defined as adverse events for which the investigator has not described the causal relationship to LEO 80185 gel as “not related”.
|
||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||
End point timeframe |
8 weeks.
|
||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis is required for this end point. |
|||||||||||||||||||||
|
|||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After ACTH-challenge, Week 4 [2] | ||||||||||
End point description |
Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After ACTH-challenge, Week 4
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
Week 4
|
||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis is required for this end point. |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After ACTH-challenge, Week 8 [3] | ||||||||||||
End point description |
Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After ACTH-challenge, Week 8
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Week 8
|
||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis is required for this end point. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Change in Albumin-corrected Serum Calcium From Baseline to Week 4 [4] | ||||||||
End point description |
Change in Albumin-corrected Serum Calcium From Baseline to Week 4
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Week 4
|
||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis is required for this end point. |
|||||||||
|
|||||||||
Notes [5] - Data available for 100 subjects |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Change in Albumin-corrected Serum Calcium From Baseline to Week 8 [6] | ||||||||
End point description |
Change in Albumin-corrected Serum Calcium From Baseline to Week 8
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Week 8
|
||||||||
Notes [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis is required for this end point. |
|||||||||
|
|||||||||
Notes [7] - Data available for 87 subjects |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Change in Albumin-corrected Serum Calcium From Baseline to End of Treatment [8] | ||||||||
End point description |
Change in Albumin-corrected Serum Calcium From Baseline to End of Treatment, Defined as the Last Value Recorded after Baseline Up to and Including Week 8.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
End of treatment
|
||||||||
Notes [8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis is required for this end point. |
|||||||||
|
|||||||||
Notes [9] - Data available for 102 subjects |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Change in 24-hour Urinary Calcium Excretion From Baseline to Week 4 [10] | ||||||||
End point description |
Change in 24-hour Urinary Calcium Excretion From Baseline to Week 4
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Week 4
|
||||||||
Notes [10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis is required for this end point. |
|||||||||
|
|||||||||
Notes [11] - Data available for 85 subjects |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Change in 24-hour Urinary Calcium Excretion From Baseline to Week 8 [12] | ||||||||
End point description |
Change in 24-hour Urinary Calcium Excretion From Baseline to Week 8
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Week 8
|
||||||||
Notes [12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis is required for this end point. |
|||||||||
|
|||||||||
Notes [13] - Data available for 72 subjects |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Change in 24-hour Urinary Calcium Excretion From Baseline to End of Treatment [14] | ||||||||
End point description |
Change in 24-hour Urinary Calcium Excretion From Baseline to End of Treatment, Defined as the Last Value Recorded after Baseline Up to and Including Week 8.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
End of Treatment
|
||||||||
Notes [14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analysis is required for this end point. |
|||||||||
|
|||||||||
Notes [15] - Data available for 85 subjects |
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Adverse Events (AEs) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Number of Adverse Events (AEs)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
8 weeks
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at Both 30 and 60 Minutes After ACTH-challenge at Week 4 | ||||||||||
End point description |
Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at Both 30 and 60 Minutes After ACTH-challenge at Week 4
|
||||||||||
End point type |
Secondary
|
||||||||||
End point timeframe |
Week 4
|
||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at Both 30 and 60 Minutes After ACTH-challenge at Week 8 | ||||||||||||
End point description |
Number of Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at Both 30 and 60 Minutes After ACTH-challenge at Week 8
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 8
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Change in Urinary Calcium:Creatinine Ratio From Baseline to Week 4 | ||||||||
End point description |
Change in Urinary Calcium:Creatinine Ratio From Baseline to Week 4
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Week 4
|
||||||||
|
|||||||||
Notes [16] - Data available for 85 subjects |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Change in Urinary Calcium:Creatinine Ratio From Baseline to Week 8 | ||||||||
End point description |
Change in Urinary Calcium:Creatinine Ratio From Baseline to Week 8
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Week 8
|
||||||||
|
|||||||||
Notes [17] - Data available for 72 subjects |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Change in Serum Alkaline Phosphatase From Baseline to Week 4 | ||||||||
End point description |
Change in Serum Alkaline Phosphatase From Baseline to Week 4
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Week 4
|
||||||||
|
|||||||||
Notes [18] - Data available for 100 subjects |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Change in Serum Alkaline Phosphatase From Baseline to Week 8 | ||||||||
End point description |
Change in Serum Alkaline Phosphatase From Baseline to Week 8
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Week 8
|
||||||||
|
|||||||||
Notes [19] - Data available for 87 subjects |
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Pharmacokinetic Evaluation AUC(0-t) | ||||||||||||||||
End point description |
AUC(0-t) values for betamethasone dipropionate, betamethasone 17-proprionate, calcipotriol, and MC1080. Betamethasone diproprionate was only detected above lower limit of quantification in 5 samples from 4 subjects and betamethasone 17-proprionate was only detected in 12 samples from 5 subjects. Calcipotriol and MC1080 were never detected above lower limit of quantification. Therefore it was not possible to calculate AUC(0-t) for betamethasone dipropionate, betamethasone 17-proprionate, calcipotriol, or MC1080. Non-calculated values have been entered as "0".
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 4
|
||||||||||||||||
|
|||||||||||||||||
Notes [20] - PK evaluation was performed in 33 subjects. Analysis set not defined in clinical trial protocol. |
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Pharmacokinetic Evaluation AUC(0-infinity) | ||||||||||||||||
End point description |
AUC(0-infinity) values for betamethasone dipropionate, betamethasone 17-proprionate, calcipotriol, and MC1080. Betamethasone diproprionate was only detected above lower limit of quantification in 5 samples from 4 subjects. Calcipotriol and MC1080 were never detected above lower limit of quantification. Therefore it was not possible to calculate AUC(0-infinity) for betamethasone dipropionate, calcipotriol, or MC1080. Non-calculated values have been entered as "0".
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 4
|
||||||||||||||||
|
|||||||||||||||||
Notes [21] - PK evaluation was performed in 33 subjects. Analysis set not defined in clinical trial protocol. |
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Pharmacokinetic Evaluation C(max) | ||||||||||||||||
End point description |
C(max) values for betamethasone dipropionate, betamethasone 17-proprionate, calcipotriol, and MC1080. Betamethasone diproprionate was only detected above lower limit of quantification in 5 samples from 4 subjects and betamethasone 17-proprionate was only detected in 12 samples from 5 subjects, therefore pharmakokinetic profiles could not be calculated. Presented C(max) values for betamethasone dipropionate and betamethasone 17-proprionate are the highest value observed at any time point. Calcipotriol and MC1080 were never detected above lower limit of quantification, therefore no C(max) values are available for calcipotriol and MC1080. Non-calculated values have been entered as "0".
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 4
|
||||||||||||||||
|
|||||||||||||||||
Notes [22] - PK evaluation was performed in 33 subjects. Analysis set not defined in clinical trial protocol. |
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Pharmacokinetic Evaluation T(max) | ||||||||||||||||
End point description |
T(max) values for betamethasone dipropionate, betamethasone 17-proprionate, calcipotriol, and MC1080. Betamethasone diproprionate was only detected above lower limit of quantification in 5 samples from 4 subjects and betamethasone 17-proprionate was only detected in 12 samples from 5 subjects. Calcipotriol and MC1080 were never detected above lower limit of quantification. Therefore it was not possible to calculate T(max) for betamethasone dipropionate, betamethasone 17-proprionate, calcipotriol, or MC1080. Non-calculated values have been entered as "0".
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 4
|
||||||||||||||||
|
|||||||||||||||||
Notes [23] - PK evaluation was performed in 33 subjects. Analysis set not defined in clinical trial protocol. |
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Pharmacokinetic Evaluation T(½) | ||||||||||||||||
End point description |
T(½) values for betamethasone dipropionate, betamethasone 17-proprionate, calcipotriol, and MC1080. Betamethasone diproprionate was only detected above lower limit of quantification in 5 samples from 4 subjects and betamethasone 17-proprionate was only detected in 12 samples from 5 subjects. Calcipotriol and MC1080 were never detected above lower limit of quantification. Therefore it was not possible to calculate T(½) for betamethasone dipropionate, betamethasone 17-proprionate, calcipotriol, or MC1080. Non-calculated values have been entered as "0".
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week4
|
||||||||||||||||
|
|||||||||||||||||
Notes [24] - PK evaluation was performed in 33 subjects. Analysis set not defined in clinical trial protocol. |
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Subjects With “Controlled Disease” According to the Investigator’s Global Assessment of Disease Severity on the Body at End of Treatment | ||||||||||
End point description |
Subjects with “Controlled disease” (i.e., “Clear” or “Almost clear” for subjects with at least “Moderate” disease at baseline, “Clear” for subjects with “Mild” disease at baseline) according to the investigator’s global assessment of disease severity on the body at end of treatment, defined as the last value recorded up to and including Week 8.
|
||||||||||
End point type |
Secondary
|
||||||||||
End point timeframe |
End of treatment
|
||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Percentage Change in PASI From Baseline to End of Treatment | ||||||||
End point description |
Percentage Change in PASI From Baseline to End of Treatment, Defined as the Last Value Recorded Up to and Including Week 8.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
End of treatment
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Subjects With “Controlled Disease” According to the Patient’s Global Assessment of Disease Severity on the Body at End of Treatment | ||||||||||
End point description |
Subjects with “Controlled disease” (i.e., “Clear” or “Almost clear” for subjects with at least “Moderate” disease at baseline, “Clear” for subjects with “Mild” disease at baseline) according to the patient’s global assessment of disease severity on the body at end of treatment, defined as the last value recorded up to and including Week 8.
|
||||||||||
End point type |
Secondary
|
||||||||||
End point timeframe |
End of treatment
|
||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
AEs/SAEs were followed up until final outcome was determined. After a subject left the trial, investigator followed up all SAEs and AEs deemed possibly/probably related to IMP for 14± 2 days or until final outcome was determined, whichever came first.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
15.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
All subjects
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
This arm contains all 107 subjects that were assigned to treatment and constitutes the safety analysis set. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
13 Nov 2013 |
Clarifications concerning efficacy, pharmacokinetic, and laboratory assessments; calculation of body surface area concomitant medications, vitamin D supplementation; details concerning discontinuation and end of treatment. |
||
12 Jun 2014 |
Specification of US sites assigned to perform HPA axis and PK assessments; clarification of the main inclusion criteria for all subjects; additional inclusion criteria for subjects not performing HPA axis and PK assessments; dose for HPA axis subgroup; limit of vitamin D analogues; Australia & New Zealand removed as participating countries; sites updated; simplification to SAE reporting. |
||
16 Feb 2015 |
Extent of BSA; definitions of controlled disease based on baseline disease severity, inclusion of subjects with mild disease severity; update of LSLV; specifications of data handling; additional inclusion criteria for HPA/ non-HPA subjects. |
||
14 Aug 2015 |
Inclusion of Central and Eastern European sites; allowing German sites to perform HPA axis and PK assessments. |
||
24 Nov 2015 |
Inclusion of Romanian sites for HPA axis and PK assessments; update of LSLV; inclusion of Synacthen® information. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |